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Peptides corresponding to the known sequence of turkey erythrocyte PI-adrenergic receptor were synthesized and the 
effects on receptor-mediated cyclase activation were measured. Peptides corresponding to the first and second intracellular 
loops (T61-71 and T138-159) inhibited at micromolar concentrations the hormone-dependent cyclase activation in tur- 
key erythrocyte membranes. In contrast, the peptide corresponding to the C-terminal part of the third intracellular loop 
(T284295) increased the cyclase activity in a hormone-independent manner. Peptides T338353 and T2-10 and a number 
of synthetic peptides unrelated to the p-adrenoceptor had no effect. 
Adrenoceptor, /%; G,-protein; Coupling domain; Synthetic peptide 
1. INTRODUCTION 
BAdrenergic activation of the adenylate cyclase 
complex involves sequential interaction of the fi- 
adrenoceptor with the stimulatory GTP-binding 
protein (G,) and the target enzyme. The agonist- 
occupied receptor promotes exchange of GTP for 
GDP at the a-subunit (as) of G,. The GTP<S com- 
plex subsequently stimulates adenylate cyclase. The 
intrinsic GTPase activity of LY~ terminates the ac- 
tivation cycle. All components of the signal trans- 
duction chain have been purified from several 
sources, and functionally reconstituted in phos- 
pholipid vesicles [ 1,2]. 
The ,&adrenoceptors from turkey erythrocyte, 
hamster lung and human placenta membranes have 
been cloned and sequenced [3-51. They have a high 
degree of homology and are similar to some other 
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G-protein-linked receptors [6,7]. This has led to the 
conclusion that they all belong to one receptor 
class. Based on the electron diffraction data of 
Henderson and Unwin [S] on bacteriorhodopsin 
and the hydrophathy profile for rhodopsin [9], a 
structural model of this receptor family was de- 
signed which includes seven hydrophobic trans- 
membrane-spanning regions connected by extra- 
cellular and intracellular hydrophilic loops. The 
turkey erythrocyteflr-receptor consists of a 50 kDa 
and a 40 kDa form which are both equally func- 
tional. The 40 kDa .receptor is formed by limited 
proteolysis and lacks the N-terminal part including 
the N-linked carbohydrate chains [lo]. The cDNA- 
deduced sequences of the GTP-binding as-subunits 
from bovine brain [ 111, bovine adrenal gland [ 121 
and human liver 1131 display greater homologies 
among each other than the amino acid sequence of 
@receptors. The cr-subunits of G, consist of two 
different forms ranging from 44.5 to 46 kDa. 
Turkey as, which has not yet been cloned, consists 
of one subunit with an apparent molecular mass of 
45 kDa [14]. The assignment of functional do- 
mains involved in receptor-G, interactions was 
based on site-directed mutagenesis [15-171 or on 
construction of Luz/&-chimeric receptors [ 181. In 
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order to explore further the receptor-G, coupling 
domains, we prepared synthetic peptides cor- 
responding to the highly conserved regions of the 
intracellular part of the &receptor and have tested 
them in competition with&receptor for interaction 
with CY~. Unlike methods based on mutagenesis 
[15-181 where artefacts in structure and function 
cannot be excluded, the use of synthetic peptides 
allows one to perform experiments with un- 
modified components [ 191. Our results presented 
here made it possible to identify regions involved in 
receptor-Gs coupling. 
2. MATERIALS AND METHODS 
&Boc-amino acids were from Novabiochem, TFA was from 
Kali-Chemie. NMP was a generous gift from BASF. Other 
reagents for peptide synthesis were from Applied Biosystems. 
[%3]GTPyS (800-1500 Ci/mmol), [w~*P]ATP (6OO.Ci/mmol) 
were from New England Nuclear. All other chemicals and bio- 
chemicals were of the highest grade commercially available and 
were obtained from the same sources as in [2,23]. 
2.1. Peptide synthesis 
Peptides were synthesized by the solid-phase Merrifield 
method on an Applied Biosystems 430A synthesizer. The 
following amino acids with protected side chains were used: Cys 
(pMeBzl); Asp (OBzl), Glu (OBzl), Ser (Bzl), Thr (Bzl), Tyr 
(2-Br-Z); His (Z); Lys (Cl-Z); Met = 0 and Arg (MTS). Amino 
acids were coupled as HOBt esters in NMP. The coupling yield 
exceeded 99% in all steps. Deprotection and cleavage from the 
resin was done with a trifluoromethanesulfonic acid/thio- 
anisole/ethanedithioI/m-cresol/TFA (1: 1: 0,5 :0,5 : 10, v/v) 
mixture [20]. The reaction was performed at 0°C for 2 h and at 
20°C for 1 h. Reduction of methionine sulfoxide was achieved 
by adding 30% (v/v) dimethyl sulfide to the reaction mixture. 
The reaction was then allowed to proceed for another 1 h at 
20°C. The crude peptides were precipitated into ether and 
purified to > 95% purity by gel filtration over Sephadex G-10 
and preparative RP-HPLC. Trifluoroacetate was exchanged 
against Cl- by chromatography on Amberlite IRA-400. Purity 
was checked by analytical HPLC and amino acid analysis. Pep- 
tide concentrations in the biological assays were calculated 
gravimetrically by adding one Cl- per positive charge to the 
molecular mass of the peptide. 
2.2. Membrane preparations 
Purified turkey erythrocyte membranes were prepared accor- 
ding to Puchwein et al. [21]. Rabbit heart membranes and 
solubilized adenylate cyclase preparation were prepared as in 
1221. 
2.3. G, preparation 
G, from turkey erythrocytes was purified according to Hanski 
et al. [14]. Deactivation of G, was carried out as described by 
Feder et al. [2]. All operations were carried out at 4OC. 
2.4. Reconstitution of purified G, in phospholipid vesicles 
Reconstitution was carried out as described by Hekman et al. 
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[23]. 15 pl of a phosphatidylethanolamine/phosphatidyl- 
serine/cholesterol hemisuccinate (12 : 8 : 5) lipid mixture 
(5 mg/ml) were added to 215 ~1 reconstitution buffer (20 mM 
Hepes, pH 7.6, 20 mM NaCl, 0.1 mM EDTA, 0.1 mM DTT 
and 0.2% Lubrol PX) which contained 3-6 pmol purified G,. 
The reconstitution mixture was kept at room temperature for 
5 min. Detergent was removed by gel filtration on a 7 x 0.4 cm 
Sephadex G-25 (fine) column. The amount of G, incorporated 
into phospholipid vesicles was determined by binding of 1 PM 
[35S]GTPyS [23]. 
2.5. Adenylate cyclase assay 
Adenylate cyclase activity in intact membranes was measured 
at 32°C for 20 min in a final volume of 150~1 containing 
20 mM Hepes, pH 7.8, 45 mM NaCl, 3 mM MgCL, 5 mM 
theophylline, 10 mM creatine phosphate, 0.2 mg/ml creatine 
kinase, 0.5 mM ATP and l-3 pCi [a-“PJATP per assay. [32P]- 
CAMP formed was isolated and determined according to 
Salomon et al. [24]. 
2.6. G, activation 
G, was activated with or without synthetic peptides as in- 
dicated. Hormone-induced activation of G, in membranes was 
achieved with lo-’ M I-isoproterenol, lo-’ M GTPyS (or 
lo-’ M GTP) and 0.5 mM MgCl2 at 37°C for the times in- 
dicated. The peptides were preincubated with the membranes 
for 30 min at 4°C and subsequently incubated for 10 min at 
30°C. The hormone-independent activation of purified G, in 
phospholipid vesicles was carried out at 32°C in the presence of 
0.5 mM MgClz and lo-’ M GTP$. 
3. RESULTS AND DISCUSSION 
Four peptides (see table 1 and fig.1) correspon- 
ding to the conserved regions of the cytoplasmic 
loops and the N-terminal segment of the C- 
terminus of the turkey Pi-receptor were synthe- 
sized. Each sequence was chosen in a way that the 
peptide contained 3-5 hydrophobic amino acids 
for anchorage in the cell membrane. The remainder 
of the peptide chain consisted mainly of hydro- 
philic amino acids (table 1). The ability of the pep- 
tides to interfere with the hormone-mediated signal 
transduction pathway was tested with intact turkey 
erythrocyte membranes. Peptide T2-10 correspon- 
ding to the extracellular N-terminal segment (fig. 1) 
and unrelated peptides of similar length and charge 
served as controls. Receptor-mediated G, activa- 
tion was followed in the presence of either GTP or 
GTPyS. 
As shown in table 1 and fig.2, peptides T61-71 
and T138-159 inhibited cyclase activity in mem- 
branes in a concentration-dependent manner with 
ICSO values of > 200 and 15 PM, respectively, sug- 
gesting that these peptides compete for receptor- 
binding domains on G,. The peptide T338-353 and 
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Table 1 
Effects of synthetic peptides on receptor-mediated cyclase activation 
Amino acid composition ICso GM) Adenylate cyclase 
activity at 100 PM 
peptide (070) 
(A) b-Receptor peptides 
T61-71 
T138-159 
T284-295 
T338-353 
(B) Control peptides 
T138-159 [Met = O”‘] 
T2-10 
H404-418 
H404-418 [Nle4i1] 
LVIAAIGRTQR 
DRYLAITSPFRYQSL 
MTRARAK 
REHKALKTLGII 
FNPIIYCRSPDFRKAF 
DRYLAITSPFRYQSL 
(Met = 0)TRARAK 
GDGWLPPDC 
LDSQGRNCSTNDSPL 
iDSQGRN(Nle) 
STNDSPL 
>200 80 
15 10 
200 130 
100 
20 15 
94 
95 
98 
Peptides indicated with T or H correspond to ,Bi-turkey or ,&hamster cDNA sequences, 
respectively. 100% adenylate cyclase activity (640 pmol/mg per min) corresponds to the 
hormonally stimulated cyclase in turkey erythrocyte membranes in the absence of synthetic 
peptides 
QSLLEASVQRSGTPAATAGGGGSRNHPGCDPPLYGDGK 
Q 
w ALKCYQDPGCCDFV 
E GTULWGSFL Q T RDLV 
A R C PDEDR N N P 
GM WL ECU im RAY FVN DVL 
LLlfA TAGF TSLD lMIP AIAS VINV FVFF 
LW PW VLC LFS SII LFF NWL PLASHA 
LLIV LLGH VTAS VLAS SFYI PLYC GYAN MEMBRANE 
AGN VLD IET IAY PLL LTF SAP 
VLVI ACAL LCVI VTCI IHIF VGHI NPII 
c T61 ST1 AID IVR VYL IGL YCR T318 
G -71 F T138 R q A RYVR T T284 S -353 - RTQR LQTLTNL -159 Y UTRAR E cl REIIRALK - 295 PDFRIRAFKRLLCFPRKADRRI. 
L L A n Ii 
A S RIQEK AhVRSTKRKSARGN PSGLTSTFCCPLPAPQGGA 
I QK G E 
TSPFRY IDRCECRFYCSQEQPQPPPLPQRQPIL ASPGGTUSDCNGCTRGGSE 
s 
AQBQKFRUlllIKLKHTAPCTCTADEFLKVIRLVTCFVAKDGNGLFTCYFRTTALI~KERE~KSESRSTKSRREELS 
Fig. 1. Position of the synthetic peptides in the proposed structure of turkey erythrocytefli-adrenergic receptor (cf. [3]). Letters in italics 
represent he synthetic peptides. 
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the unrelated control peptides showed no effect up 
to 200 ,uM. Peptide T284-295 showed an opposite 
effect enhancing cyclase activity in a 
concentration-dependent manner. Peptide 
T284-295 was able to activate cyclase in turkey 
erythrocyte membranes, presumably via G,- 
protein, without agonist stimulation and even in 
the presence of &adrenergic antagonists (fig.3). 
Agonist-independent cyclase stimulation by 
T284-295 in native turkey erythrocyte membranes 
was confirmed in reconstituted liposomes. Phos- 
pholipid vesicles containing purified G, prepared 
from turkey erythrocytes were preincubated with 
T284-295 for 10 min at 30°C and the time course 
of GTPyS binding was followed by activation of a 
crude myocardial cyclase preparation according to 
Metzger et al. [22]. Since peptide T284-295 in- 
creased 2-fold the initial rate of GTP+ binding 
measured after 2 min, it may be concluded that 
T284-295 can act as a receptor substitute. 
A possible influence of the receptor peptides on 
the coupling of G, to the catalytic subunit (C) in 
membranes was tested by using AlF:-activated G,. 
The peptides T61-71, T138-159 and T284-295 
were allowed to interact with fluoride-activated 
membranes for 30 min at 4°C and the extent of 
cyclase activation was measured (fig.4). Only pep- 
tide T138- 159 inhibited slightly the AIFT-induced 
cyclase activation (22% at 200,~M). This effect 
could be explained assuming that the peptide 
PEPTIDES : 
338- 353 
2- 10 
61- 71 
130- 159 
I I HI1111 
10 100 
Peptide (,uM) 
Fig.2. Effects of synthetic &receptor peptides on hormone- 
mediated cyclase activtion in turkey erythrocyte membranes. 
Membranes were preincubated with peptides for 30 min at 4°C 
and hormone-dependent G, activation was carried out for 5 min 
at 37°C with lo-’ M GTPyS and 10e5 M I-isoproterenol or 
10m5 M I-propranolol. Agonist-dependent activation is plotted 
as the difference between the activities in the presence of either 
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isoproterenol or propranolol. 
- 
I I,:” I I I I J 
0 0.1 1 10 100 mu 
Peptide Tm-m (NM) 
Fig.3. Stimulatory effect of peptide T284-295 on hormone- 
independent cyclase activity in turkey erythrocyte membranes. 
The membranes were preincubated with T284-295 for 30 min at 
4°C and the cyclase assay was performed for 20 min at 32°C in 
the presence of 10d5 M GTP and 10m5 M I-propranolol. 
T138-159 when bound to G, may cause some 
sterical constraints resulting in reduced coupling of 
G,-protein with the catalytic subunit. 
We conclude from these resuits that the first and 
second intracellular loops and the C-terminal por- 
tion of the third intracellular loop represented by 
the peptides T61-71, T138-159 and T284-295 are 
essential for hormonal signal transmission or its 
modulation; in contrast, the C-terminal part of the 
seventh membrane-spanning helix (up to Phe353) 
had no effect. Our results are in agreement with 
those reported with site-directed mutants of the 
human and hamster &-receptor [15-171, however 
peptide T338-353 did not interfere with receptor- 
G, coupling under our experimental conditions. 
PEPTIDES 
2.94 - 995 
61- 71 
138-159 
Peptide (NM) 
Fig.4. Effects of synthetic P-receptor peptides on G,-mediated 
cyclase activation in turkey erythrocyte membranes. 
AlFh-activated membranes were incubated with peptides for 
30 min at 4°C and the cyclase assay was carried out for 20 min 
at 32°C as described in section 2. 
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Experiments with mutants demand caution, since 
reduced adenylate cyclase activity as described by 
O’Dowd et al. [17] may not be the consequence of 
site-specific interactions, but rather of overall 
changes in receptor structure and subsequently of 
receptor anchoring and disposition in the mem- 
branes. The ability of peptide T284-295 (C- 
terminal part of the third loop) to activate Gs in a 
hormone-independent fashion can be explained by 
the assumption that the conformation of T284-295 
represents that of an activated receptor. A similar 
effect has recently been described for mastoparan, 
a peptide isolated from wasp venom 1251, which is 
capable of mimicking hormone-activated receptor. 
The amino acid pattern and the secondary struc- 
ture prediction of mastoparan are very similar to 
T284-295, since both peptides form a positively 
charged a-helix. In addition, the studies of Kobilka 
et al. [18] on G, activation with chimeric receptors 
point to the importance of the sixth transmem- 
brane helix and its N-terminal portion: all chimeric 
CY~Z- and flz-adrenergic receptors, which are able to 
activate adenylate cyclase, contain the segment cor- 
responding to T284-295. Since small peptides like 
the T284-295 undecamer may adopt any possible 
conformation of the P-receptor chain, it would be 
sufficient if a small fraction of the peptide is in the 
‘active’ conformation and is able to replace func- 
tionally the receptor. We expect to localize more 
definitively the functional domains participating in 
receptor-G, coupling by studies with additional 
peptides, especially those corresponding to parts of 
the third intracellular loop and C-terminal segment 
of the receptor. 
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